key: cord-1017068-8rgekrzo
authors: Kara, Emre; Inkaya, Ahmet Cagkan; Demirkan, Prof. Dr. Kutay
title: May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?
date: 2020-04-30
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106003
sha: ecda79086650aa591fdfaa71b9adf1ce28de44f0
doc_id: 1017068
cord_uid: 8rgekrzo

nan

Besides respiratory manifestations, COVID-19 has cardiac implications which have been shown and reviewed by Guo et al. and Madjid et al. [1, 2] . Hypertension, diabetes, cardiovascular diseases and cerebrovascular diseases, were highlighted as risk factors for fatality. With a limited sample sized study Guo et al. demonstrated effects of comorbid conditions on cardiac outcomes. Their results could be biased by certain confounders. Cardiotoxicity might also be associated with drugs used in treatment of comorbidities rather than the comorbidity itself. In order to overcome confounders, multivariate analysis is needed which also include comedications along with comorbidities. COVID-19 has high fatality among elderly (>60 years). Excess fatality might also be associated with polypharmacy -commonly seen in elderly-and drug related problems besides comorbidities and the disease itself [3] . hydroxychloroquine related QT-prolongation may also manifest even after hospitaldischarge. We suggest follow-up ECG evaluations for people who receive hydroxychloroquine and/or azithromycin. Telemedicine fueled with ECG monitoring could be implemented for follow-ups.

Funding: No funding

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19

Chloroquine And Hydroxychloroquine Toxicity

Ethical Approval: Not required